Clearside Biomedical

Focus: Clearside Biomedical is a specialized biotechnology company focused on ocular drug delivery technology, with a concentrated pipeline in ophthalmology targeting conditions like uveitis, diabetic macular edema, and age-related macular degeneration.

Ophthalmology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Clearside Biomedical

AI assessmentNot Hiring

No open roles listed right now. Follow Clearside Biomedical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CLS-AX

Neovascular Age-related Macular Degeneration

N/A

Clinical Trials (1)

NCT05131646Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study

N/A

Help build intelligence for Clearside Biomedical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep expertise in suprachoriodal injection technology, a differentiated delivery mechanism with potential to reshape ophthalmology treatment paradigms
Phase 3 pipeline with 4 active programs in high-value indications (uveitis, macular edema, nAMD), providing near-term value creation and exit potential
Focused therapeutic area (ophthalmology) enables development of genuine domain expertise and narrow competitor base

Watch Out For

Zero active job openings at time of analysis suggests potential hiring freeze, restructuring, or pre-liquidity contraction
Completely private company funding status and lack of public financial data create uncertainty around cash runway, burn rate, and organizational stability

Generated by Claude from Clearside Biomedical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

4 mg CLS-TA Suprachoriodal Injection

Uveitis

N/A

Clinical Trials (1)

NCT02952001MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301

N/A

Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent

Macular Edema

N/A

Clinical Trials (1)

NCT02956330Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201

N/A

CLS-AX

Neovascular Age-related Macular Degeneration

Phase 1/2

Clinical Trials (1)

NCT04626128Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD

Phase 1/2

IVT Aflibercept

Diabetic Macular Edema

Phase 1/2

Clinical Trials (1)

NCT02949024Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema

Phase 1/2

triamcinolone acetonide

Uveitis

Phase 1/2

Clinical Trials (1)

NCT01789320Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis

Phase 1/2

4 mg CLS-TA

Uveitis

Phase 2

Clinical Trials (1)

NCT02255032Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis

Phase 2

IVT aflibercept

Diabetic Macular Edema

Phase 2

Clinical Trials (1)

NCT03126786Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema

Phase 2

4 mg CLS-TA

Macular Edema

Phase 2

Clinical Trials (1)

NCT02303184Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

Phase 2

CLS-AX

Neovascular Age-related Macular Degeneration

Phase 2

Clinical Trials (1)

NCT05891548Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration

Phase 2

4 mg CLS-TA Suprachoriodal Injection

Uveitis

Phase 3

Clinical Trials (1)

NCT03097315Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis

Phase 3

suprachoroidal CLS-TA

Macular Edema

Phase 3

Clinical Trials (1)

NCT02980874Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

Phase 3

suprachoroidal CLS-TA

Macular Edema

Phase 3

Clinical Trials (1)

NCT03203447Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

Phase 3

4mg CLS-TA Suprachoriodal Injection

Uveitis

Phase 3

Clinical Trials (1)

NCT02595398Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 14 clinical trials

Top TAs: Ophthalmology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Ophthalmology

12 pipeline

Marketed

Pipeline